SCR 43 is a California concurrent resolution that proclaims April 2025 as Parkinson’s Disease Awareness Month. The text is ceremonial: it compiles epidemiological and economic findings, cites research milestones and the state’s Parkinson’s/Neurodegenerative Disease Registry, and directs transmittal of the resolution.
The resolution matters because it elevates the state’s registry and research partnerships in an official legislative finding. For stakeholders—research institutions, public health authorities, advocacy groups, and health systems—the resolution signals legislative attention that may influence outreach priorities, data‑sharing requests, and public messaging despite carrying no new funding or regulatory mandates.
At a Glance
What It Does
SCR 43 formally proclaims April 2025 as Parkinson’s Disease Awareness Month in California and contains a series of "whereas" findings summarizing disease prevalence, costs, research developments, and the state registry. The resolution includes a transmittal instruction to the Secretary of the Senate but creates no new programs or budgetary obligations.
Who It Affects
Directly implicated parties are people with Parkinson’s and their caregivers, the California Department of Public Health and entities reporting to the state Neurodegenerative Disease Registry, research institutions that receive registry data, advocacy organizations, and major health systems listed in the resolution. The measure does not impose new legal duties on private parties beyond existing registry reporting rules.
Why It Matters
By spotlighting registry activity, partnership networks, and a validated biomarker, the resolution raises the visibility of state data assets and research capacity—information that may drive outreach, data access requests, research recruitment, and philanthropic or agency priorities even though the resolution itself is nonbinding.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SCR 43 is a one‑page legislative proclamation. It opens with a string of findings that summarize what sponsors see as the most important facts about Parkinson’s disease: how it presents clinically, recent estimates of incidence and prevalence, the estimated national and state economic burden, and the status of research efforts.
Those findings are written to justify and contextualize the single operative act—the proclamation of April 2025 as Parkinson’s Disease Awareness Month.
The resolution gives particular attention to California’s data infrastructure: it recounts that the California Parkinson’s Disease Registry was established through the state budget in 2017, became operational in 2018, and has since been expanded into the California Neurodegenerative Disease Registry. The text lists that the registry has formed reporting partnerships with more than 500 entities—including named integrated health systems—and that processed records are made available to research institutions after state public health processing.SCR 43 also catalogs private research contributions and milestones: aggregate fundraising figures attributed to a major foundation, recurring annual grants to specific universities for a longitudinal study, and the 2023 announcement validating a biomarker detectable in living people with Parkinson’s.
The resolution ends by formally declaring April 2025 as Parkinson’s Disease Awareness Month in California and directing the Secretary of the Senate to transmit copies to the author for distribution.Because this is a concurrent resolution, it has no appropriation or regulatory effect. Its practical impact will be through attention it generates: public‑education activity, media coverage, research and advocacy agendas, and potential increases in data‑sharing or recruitment requests tied to the registry and the research community.
The Five Things You Need to Know
The resolution proclaims April 2025 as Parkinson’s Disease Awareness Month across California.
It records that the California Parkinson’s Disease Registry was created in 2017, began operations in 2018, and has since been expanded into the California Neurodegenerative Disease Registry.
The bill lists more than 500 reporting partners to the registry, naming major health systems such as Sutter Health, Kaiser Permanente, Dignity Health, Scripps Health, and Stanford Health Care.
SCR 43 cites funding and research milestones: over $310 million raised in California by a major foundation and $2 million annual grants to UCSF, UCSD, and USC for participation in a longitudinal study (PPMI).
The resolution instructs the Secretary of the Senate to transmit copies of the resolution to the author for appropriate distribution; it contains no funding authorization or new statutory duties.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Legislative findings on disease burden, costs, and research
This section compiles factual statements the Legislature wants on the record: clinical symptoms, rising incidence and prevalence estimates, national and state cost estimates, caregiving impacts, and a summary of research activity. Practically, these findings form the justification for the proclamation and summarize data points stakeholders may cite when seeking attention or resources; they do not create regulatory requirements or change how the registry operates.
Recognition of California’s Parkinson’s/Neurodegenerative Disease Registry
These clauses trace the registry’s origin (budgeted in 2017, operational in 2018), describe its expansion to cover related diseases, and list the scale of reporting partnerships and records collected. For public‑health and hospital compliance officers, the functional implication is visibility: the Legislature has put on the record the registry as a statewide data asset, which may increase inquiries from researchers and advocates even though the resolution does not alter reporting rules or funding.
Acknowledgement of private research contributions and milestones
The resolution calls out the Michael J. Fox Foundation’s fundraising totals, recurring institutional grants tied to a large biomarker study (PPMI), and the 2023 biomarker validation announcement. This section is effectively a legislative imprimatur endorsing private–public research activity; it may be used by institutions to justify continued participation or to bolster grant applications but does not create new state obligations.
Official proclamation and administrative step
The single operative sentence declares April 2025 as Parkinson’s Disease Awareness Month in California. A short follow‑up provision instructs the Secretary of the Senate to transmit copies of the resolution to the author for distribution. This is an administrative step to formalize the proclamation; it imposes negligible administrative costs and no programmatic duties on state agencies.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with Parkinson’s disease and their caregivers — the resolution raises public awareness that can improve community outreach, advocacy leverage for services, and visibility for fundraising drives supporting patient care.
- Research institutions and academic centers participating in longitudinal studies — the resolution highlights validated biomarkers and registry data, potentially easing recruitment and justifying institutional investment or grant proposals.
- Advocacy organizations (e.g., foundations named in the text) — legislative recognition amplifies messaging, may help with fundraising and partnership development, and legitimizes public‑education campaigns.
- State public health officials and registry administrators — the bill elevates the registry as a state resource, which can strengthen arguments for future funding or policy attention to surveillance infrastructure.
Who Bears the Cost
- State legislative and administrative offices — minor administrative tasks (printing/transmission) and staff time to support outreach tied to the proclamation are borne without new appropriations.
- Health systems and reporting entities — heightened attention may generate more ad hoc data inquiries and requests for research collaboration, increasing staff time for data access, legal review, and compliance work.
- Public health agencies operating the registry — the resolution may spur additional data requests and researcher engagement without attaching new funding, creating potential capacity strains for analysis, data governance, and researcher support.
Key Issues
The Core Tension
The central dilemma is symbolic recognition versus concrete action: SCR 43 raises the profile of Parkinson’s disease and highlights a robust state registry and research milestones, but by remaining ceremonial it shifts responsibility for follow‑through to agencies, health systems, and private funders—creating expectations the Legislature does not fund and leaving unresolved how to balance expanded research access with privacy and operational capacity.
The resolution is symbolic, which is both its strength and its limit. As a formal proclamation, it signals legislative priorities, but it does not allocate funds, change reporting requirements, or create new statutory authorities.
That gap creates a recurring implementation question: will stakeholders treat the proclamation as a prompt for funded action or merely as rhetorical support? If organizations and agencies act on the attention, they will likely need new resources that the resolution does not provide.
A second practical tension concerns the registry and data governance. The bill notes that processed records are made available to research institutions after State Department of Public Health processing, but it does not describe consent frameworks, de‑identification standards, access controls, or commercial‑use restrictions.
Increased visibility tends to generate more data requests; without clearer governance, the registry could face privacy litigation, representativeness concerns, or operational bottlenecks. Finally, the resolution leans on private philanthropy and named foundations; that public–private mix has helped progress research but raises sustainability questions if public funding does not follow.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.